iSpecimen Inc. (ISPC)
USD 1.21
(0.23%)
USD 1.21
(0.23%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 196.24 Thousand USD | 5.59% |
| 2022 | 185.84 Thousand USD | -94.57% |
| 2021 | 3.42 Million USD | -73.19% |
| 2020 | 12.76 Million USD | 20.55% |
| 2019 | 10.59 Million USD | 51.99% |
| 2018 | 6.96 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 156.7 Thousand USD | -20.15% |
| 2024 Q2 | 29.13 Thousand USD | -81.41% |
| 2023 FY | 196.24 Thousand USD | 5.59% |
| 2023 Q4 | 196.24 Thousand USD | -16.26% |
| 2023 Q3 | 234.34 Thousand USD | 117.03% |
| 2023 Q2 | 107.97 Thousand USD | -26.73% |
| 2023 Q1 | 147.37 Thousand USD | -20.7% |
| 2022 Q2 | 3.68 Million USD | -0.9% |
| 2022 Q4 | 185.84 Thousand USD | -94.92% |
| 2022 Q1 | 3.72 Million USD | 8.78% |
| 2022 FY | 185.84 Thousand USD | -94.57% |
| 2022 Q3 | 3.65 Million USD | -0.92% |
| 2021 Q2 | 3 Million USD | -73.71% |
| 2021 FY | 3.42 Million USD | -73.19% |
| 2021 Q1 | 11.41 Million USD | -10.62% |
| 2021 Q4 | 3.42 Million USD | -0.17% |
| 2021 Q3 | 3.42 Million USD | 14.28% |
| 2020 FY | 12.76 Million USD | 20.55% |
| 2020 Q3 | 12.76 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q4 | 12.76 Million USD | 0.01% |
| 2019 FY | 10.59 Million USD | 51.99% |
| 2019 Q4 | 10.59 Million USD | 0.0% |
| 2018 FY | 6.96 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| bioAffinity Technologies, Inc. | 1.57 Million USD | 87.569% |
| T2 Biosystems, Inc. | 49.49 Million USD | 99.604% |
| Aspira Women's Health Inc. | 2.26 Million USD | 91.34% |
| Biodesix, Inc. | 60.69 Million USD | 99.677% |
| Castle Biosciences, Inc. | 15.31 Million USD | 98.718% |
| Exact Sciences Corporation | 2.55 Billion USD | 99.992% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 99.979% |
| Illumina, Inc. | 2.26 Billion USD | 99.991% |
| Standard BioTools Inc. | 98.21 Million USD | 99.8% |
| 23andMe Holding Co. | 76.51 Million USD | 99.744% |
| NeoGenomics, Inc. | 611.67 Million USD | 99.968% |
| Neogen Corporation | 906.23 Million USD | 99.978% |
| Inotiv, Inc. | 417.64 Million USD | 99.953% |
| Psychemedics Corporation | 2.29 Million USD | 91.46% |
| RadNet, Inc. | 1.49 Billion USD | 99.987% |
| Star Equity Holdings, Inc. | 3.6 Million USD | 94.562% |
| Prenetics Global Limited | 2.36 Million USD | 91.718% |
| OpGen, Inc. | 13.04 Million USD | 98.495% |
| Neuronetics, Inc. | 62.47 Million USD | 99.686% |
| Precipio, Inc. | 1.11 Million USD | 82.415% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | 77.48% |
| Exagen Inc. | 23.72 Million USD | 99.173% |
| Bionano Genomics, Inc. | 87.94 Million USD | 99.777% |
| CareDx, Inc | 34.22 Million USD | 99.427% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 94.06 Million USD | 99.791% |
| Guardant Health, Inc. | 1.35 Billion USD | 99.986% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -47.115% |
| Natera, Inc. | 441.99 Million USD | 99.956% |
| Fulgent Genetics, Inc. | 14.9 Million USD | 98.684% |
| Sera Prognostics, Inc. | 1.85 Million USD | 89.438% |
| OPKO Health, Inc. | 326.56 Million USD | 99.94% |
| Personalis, Inc. | 48.96 Million USD | 99.599% |
| Aclaris Therapeutics, Inc. | 426 Thousand USD | 53.933% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | 84.145% |
| Myriad Genetics, Inc. | 145 Million USD | 99.865% |
| ICON Public Limited Company | 3.93 Billion USD | 99.995% |
| Star Equity Holdings, Inc. | 3.6 Million USD | 94.562% |
| MDxHealth SA | 41.26 Million USD | 99.524% |
| Prenetics Global Limited | 2.36 Million USD | 91.718% |
| DarioHealth Corp. | 29.54 Million USD | 99.336% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | 50.243% |
| Medpace Holdings, Inc. | 142.12 Million USD | 99.862% |
| Mainz Biomed B.V. | 7.42 Million USD | 97.355% |
| Trinity Biotech plc | 67.42 Million USD | 99.709% |
| Sotera Health Company | 2.32 Billion USD | 99.992% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | 87.569% |